CCR2 and metabolic dysfunction-associated steatohepatitis: In the TANDEM trial (NCT03517540), LJN-452 with cenicriviroc, a dual CCR2/CCR5 antagonist, was used to study patients with biopsy-proven NASH and liver fibrosis [124,271].